Gilead Sciences | 8-K: Gilead Sciences Reports Fourth Quarter and Full Year 2024 Results

Feb 11 16:07 ET

Gilead Sciences | 8-K/A: Gilead Sciences Appoints Dietmar Berger Van As Chief Medical Officer

Dec 13, 2024 13:37 ET

Gilead Sciences | 8-K: Signing of The Tenth Supplementary Deed

Nov 20, 2024 16:18 ET

Gilead Sciences | 8-K: Gilead Sciences Reports Third Quarter 2024 Financial Results

Nov 6, 2024 16:14 ET

Gilead Sciences | 8-K: Gilead Sciences Reports Second Quarter 2024 Financial Results

Aug 8, 2024 16:39 ET

Gilead Sciences | 8-K: Gilead Sciences Announces Dr Merdad V. Parsey is Leaving the Company

Jul 17, 2024 09:06 ET

Gilead Sciences | 8-K: Poll Results of 2024 Annual Meeting of Shareholders

May 9, 2024 16:41 ET

Gilead Sciences | 8-K: Gilead Sciences Announces First Quarter 2024 Financial Results

Apr 25, 2024 16:09 ET

Gilead Sciences | DEF 14A: Definitive information statements

Mar 28, 2024 16:16 ET

Gilead Sciences | DEFA14A: Others

Mar 28, 2024 16:11 ET

Gilead Sciences | 8-K: Gilead Sciences Announces Completion of Acquisition of CymaBay Therapeutics and Enters into an Agreement and Plan of Merger with Wholly-Owned Subsidiary Pacific Merger Sub

Mar 22, 2024 09:22 ET

Gilead Sciences | PRE 14A: Preliminary proxy statements relating to merger or acquisition

Mar 18, 2024 16:11 ET

Gilead Sciences | 8-K: Kevin E. Lofton Will Retire from the Board

Mar 14, 2024 16:14 ET

Gilead Sciences | 8-K: Agreement and Plan of Merger

Feb 12, 2024 08:39 ET

Gilead Sciences | 8-K: Gilead Sciences Reports Fourth Quarter and Full Year 2023 Financial Results

Feb 6, 2024 16:10 ET

Gilead Sciences | 8-K: Gilead Sciences Appoints Dr. Ted W. Love to Board of Directors

Feb 2, 2024 16:22 ET

Gilead Sciences | 8-K: Gilead Sciences Announces Third Quarter 2023 Financial Results

Nov 7, 2023 16:03 ET

Gilead Sciences | 8-K: Entry into Underwriting Agreements

Sep 14, 2023 09:00 ET

Gilead Sciences | 8-K: Presentation of Sacituzumab Govitecan + Pembrolizumab in 1L Metastatic Non-Small Cell Lung Cancer: Preliminary Results of the EVOKE-02 Study in WCLC

Aug 16, 2023 17:19 ET

Gilead Sciences | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans

Aug 7, 2023 16:23 ET